ACTION - Nifedipine for stable CAD
Bottom line: In patients with stable angina already treated with at least 1 maintenance anti-anginal drug, nifedipine for 4.5-6 years did not reduce major CV events.
Patients
- Inclusion:
- Age 35+ y
- Angina stable for at least 1 month
- Needing treatment of angina (note: not necessarily uncontrolled or symptomatic at baseline)
- Plus one of the following
- Hx of MI
- No hx of MI, but angiographically-confirmed CAD
- No hx of MI or angiography, but CAD by positive exercise test or perfusion defect
- Exclusion
- Overt HF
- LVEF <40%
- Any majr CV event or intervention in the past 3 months
- Planned coronary angiography or intervention
- Clinically significant valvular or pulmonary disease
- Unstable insulin-dependent diabetes
- Any GI disorder that could impair absorption of long-acting nifedipine formulation
- Any other condition other than CAD that could limit life expectancy
- Symptomatic orthostatic hypotension, or supine SBP <90 mm Hg
- SBP 200+ mm Hg, DBP 105+ mm Hg
- Renal dysfunction (SCr >2x ULN)
- Liver dysfunction (ALT/AST >3x ULN)
- From 1996-1998, ? screened -> 7797 randomized -> 7665 analyzed
- "Average" patient
- Age 63.5 y
- Male 80%
- Enrollment criterion met
- Hx of MI ~50%
- No MI, angiographically-confirmed CAD 33%
- No MI or angiography, but positive exercise or perfusion defect 17%
- Current NYHA class II-III symptoms 46%
- Hx of angina attacks 93%
- Baseline vitals
- BP 137/80
- HR 64
- Mean LVEF 48%
- Concomitant meds
- Any anti-anginal drug 99%
- Beta-blocker 79%
- Nitrate (daily maintenance) 38%
- Nitrate PRN use 56%
- ASA 86%
- Statin 63%
- Any BP lowering 30% - ACEI 20%
- Any anti-anginal drug 99%
Generalizability: Who do these results apply to?
- Normotensive individuals with CAD without LV dysfunction, most of whom with a previous MI (of unreported age, but at least 3 months ago), already taking at least 1 daily anti-anginal drug.
- Does not apply to patients with:
- Recent MI
- Angina at rest or with minimal activity
- Optimized secondary prevention therapy
- Overt HF or reduced LVEF
- Patients with uncontrolled HTN
Interventions
- I: Nifedipine
- Initial dose: 30 mg PO once daily
- If initial dose tolerated, increased to 60 mg PO once daily within 6 weeks
- Dose could be reduced or interrupted
- C: Matching placebo
- The following drugs couldn't be used during the study:
- Non-study calcium-channel blocker (if on prior to study, 2-week washout before study enrollment)
- Digoxin (unless used for supraventricular arrhythmias such as afib) or other positive inotropes
- Antiarrhythmics, class I or III (exceptions: amiodarone or sotalol)
- Cimetidine
- Anticonvulsants
- Antipsychotics
- Rifampicin
Results @ planned follow-up of 4.5-6 y (97% of patients met minimal planned follow-up)
- Effect on vitals
- BP reduced by ~5/3 mm Hg (not reported; estimated from Figure 2)
- Patients with BP <140/90: 65% vs 53%
- HR increased by 1 bpm
- BP reduced by ~5/3 mm Hg (not reported; estimated from Figure 2)
- No statistically significant difference in primary composite outcome and multiple components of this outcome
- Primary outcome (time to first occurrence of either all-cause death, MI, refractory angina, new over HF, debilitating stroke, or peripheral revascularization): ~22% in both groups (hazard ratio 0.97, 95% confidence interval 0.88-1.07, p=0.54)
- Death: 8% vs 7.6% (HR 1.07, 95% CI 0.91-1.25)
- Debilitating stroke: 2% vs 2.6% (HR 0.78, 0.58-1.05)
- MI: 7.0% vs 6.7% (HR 1.04, 0.88-1.24)
- Refractory angina (defined as angina at rest, prolonged administration of IV nitrates or equivalent plus a coronary angiogram <1 week after onset of symptoms): 3.9% vs 4.5% (HR 0.86, 0.69-1.07)
- PCI: 10.1% vs 10.9% (HR 0.92, 0.80-1.06)
- Certain components of the primary composite outcome were statistically reduced with nifedipine
- New overt HF: 2.2% vs 3.2% (HR 0.71, 0.54-0.94)
- Coronary angiography: 23.4% vs 27.8% (HR 0.82, 0.75-0.90)
- CABG: 7.7% 9.7% (HR 0.79, 0.68-0.92)
- Subgroups: Of 11 subgroup analyses, only separation of patients based on BP 140/90 or greater vs <140/90 had a significant test for interaction (p=0.015), suggesting benefit of nifedipine in patients with CAD + HTN
Issues with internal validity?
- No: Randomized, allocation-concealed, blinded (patients, clinicians, investigators) trial with unclear loss-to-follow-up (~5% terminated study earlier than intended) analyzed using a modified intention-to-treat population (all patients who took at least 1 dose of study drug)
- Note: No run-in phase
Additional considerations
A deeper look at secondary outcomes and subgroup analyses does not clearly support either the role of nifedipine as a antihypertensive drug in patients with CAD, or as an effective anti-anginal.
Antihypertensive: Subgroup analysis demonstrated potential benefit in patients with BP 140/90 mm Hg or greater, but there was no statistically significant reduction in debilitating stroke in the overall study population (the outcome most closely associated with HTN in observational studies).
Anti-anginal: Though a reduction in the need for coronary angiography and CABG both suggest a reduction in myocardial ischemia, there was no reduction in the proportion of patients with MI, refractory angina, or PCI.
The results of this study conflict with those of the previously-covered CAMELOT trial of amlodipine, which argues against a class effect of dihydropyridine calcium-channel blockers in CAD.